BF-175
BF-175 is a selective SIRT1 agonist. BF175 increases SIRT1-mediated activation of PGC1-α, induces Apoptosis, induces Autophagy and inhibits SREBP activity. BF-175 protects against high glucose-mediated mitochondrial injury. BF-175 attenuates diabetic kidney disease progression. BF175 inhibits endometrial carcinoma[1][2].
Product Specifications
CAS Number
1333375-02-2
UNSPSC
12352005
Target
Apoptosis; Autophagy; Fatty Acid Synthase (FASN) ; PGC-1α; Sirtuin
Related Pathways
Apoptosis; Autophagy; Cell Cycle/DNA Damage; Epigenetics; Metabolic Enzyme/Protease
Field of Research
Cancer; Metabolic Disease
Smiles
CC1(OB(C2=CC=C(C=C2)/C=C/C3=CC(Cl)=CC(Cl)=C3)OC1(C)C)C
Molecular Formula
C20H21BCl2O2
Molecular Weight
375.10
References & Citations
[1]Hong Q, et al. Increased podocyte Sirtuin-1 function attenuates diabetic kidney injury. Kidney Int. 2018 Jun;93 (6) :1330-1343. |[2]Wang Q, et al. BF175 inhibits endometrial carcinoma through SREBP-regulated metabolic pathways in vitro. Mol Cell Endocrinol. 2021 Mar 1;523:111135.
Shipping Conditions
Room temperature
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Isoform
SIRT1
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
BNC040391-100 1x 100 µL
CD81 / TAPA-1 (1.3.3.22), CF405S conjugate, 0.1mg/mL
Sign In for Pricing
View Details 
BNC040034-100 1x 100 µL
Cytokeratin 8/18 (C-51), CF405S conjugate, 0.1mg/mL
Sign In for Pricing
View Details 
BNC470745-100 1x 100 µL
CD45 / LCA (2B11 + PD7/26), CF647 conjugate, 0.1mg/mL
Sign In for Pricing
View Details 
BNC400257-100 1x 100 µL
Cytokeratin, HMW (AE-3), CF640R conjugate, 0.1mg/mL
Sign In for Pricing
View Details